Reuters logo
BRIEF-Kite says anti-CD19 CAR T-cell therapy shows durable remissions in advanced non-Hodgkin lymphoma
2016年6月6日 / 中午11点57分 / 1 年前

BRIEF-Kite says anti-CD19 CAR T-cell therapy shows durable remissions in advanced non-Hodgkin lymphoma

June 6 (Reuters) - Kite Pharma Inc :

* Kite/NCI Anti-CD19 CAR T-cell therapy demonstrates durable complete remissions in advanced Non-Hodgkin Lymphoma

* 9 of 19 patients (47%) with diffuse large B-cell lymphoma achieved complete responses, which are all ongoing with duration of 7 to 20 months

* Results showed that CAR T-cell therapy was effective in inducing a high response rate in patients with advanced non-Hodgkin lymphoma Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below